Clareo Health | Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment
Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment
Patient receiving stable antiretroviral therapy (i.e., no change in treatment strategy or dosage regimen) for at least 6 months.
Patient receiving antiretroviral therapy based on emtricitabine or lamivudine.
Patient identified as compliant based on patient follow-up data: (i) patient's reported adherence to the infectious disease physician (i.e., simple self-report), (ii) virological data (i.e., absence of blips in the last 18 months), (iii) pharmacological data (i.e., plasma antiretroviral concentrations within the expected range) if concentrations were previously measured as part of the patient's follow-up.
Patient agreeing not to cut their hair to less than 6 cm of remaining length during the 6 months of the study.
Patient agreeing to have their hair sampled at the end of the 6 months.
Patients over 18 and under 70 years of age.
Individuals who have not objected.
Individuals enrolled in the French Health Insurance
You may not be if
Pregnant women.
Patients planning to color/bleach their hair in the next 6 months.
Patients planning to have their hair straightened/restyled in the next 6 months.
